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OBJECTIVES We sought a better understanding of the coupling between right ventricular ejection fraction
(RVEF) and pulmonary artery pressure (PAP), as it might improve the accuracy of the
prognostic stratification of patients with heart failure.
BACKGROUND Despite the long-standing view that systolic function of the right ventricle (RV) is almost
exclusively dependent on the afterload that this cardiac chamber must confront, recent studies
claim that RV function is an independent prognostic factor in patients with chronic heart
failure.
METHODS Right heart catheterization was performed in 377 consecutive patients with heart failure.
RESULTS During a median follow-up period of 17 6 9 months, 105 patients died and 35 underwent
urgent heart transplantation. Pulmonary artery pressure and thermodilution-derived RVEF
were inversely related (r 5 0.66, p , 0.001). However, on Cox multivariate survival analysis,
no interaction between such variables was found, and both turned out to be independent
prognostic predictors (p , 0.001). It was found that RVEF was preserved in some patients
with pulmonary hypertension, and that the prognosis of these patients was similar to that of
the patients with normal PAP. In contrast, when PAP was normal, reduced RV function did
not carry an additional risk.
CONCLUSIONS These observations emphasize the necessity of combining the right heart hemodynamic
variables with a functional evaluation of the RV when trying to define the individual risk of
patients with heart failure. (J Am Coll Cardiol 2001;37:183–8) © 2001 by the American
College of Cardiology
In patients with primary dilated cardiomyopathy or isch-
emic heart disease, left ventricular (LV) dysfunction is the
original physiologic disorder leading to the clinical syn-
drome of chronic heart failure. In fact, a reduced ejection
fraction of the LV is a powerful predictor of death in a
general population of patients with heart failure; however,
its prognostic value loses strength when applied to patients
with advanced heart failure, so that it may not be used to
select the proper time for heart transplantation (1). The
identification of patients with heart failure at higher risk of
death has become an area of active investigation over the last
two decades. Recently, a number of studies have provided
evidence that right ventricular ejection fraction (RVEF),
either directly measured (by radionuclide angiography or
rapid response thermodilution) or indirectly estimated (by
echocardiography), is an independent prognostic factor in
patients with moderate to severe heart failure (2–6). In
addition, in patients with advanced disease, thermodilution-
derived RVEF proved to be the single most important
determinant of short-term prognosis among all of the
hemodynamic variables obtained during right heart cathe-
terization (4).
Uncertainty about clinical acceptance of these data stems
from the long-standing view maintaining that the systolic
function of the right ventricle (RV) is almost exclusively
dependent on the afterload that this cardiac chamber must
confront (7–12). Pulmonary hypertension frequently com-
plicates heart failure and is generally considered “per se” an
indicator of poor prognosis (13,14).
We therefore designed a study aimed at evaluating
whether a better understanding of the coupling between RV
function and pulmonary artery pressure (PAP) could im-
prove the prognostic stratification of patients with chronic
heart failure.
METHODS
Patients. The study enrolled 379 consecutive outpatients
referred to the Cardiology Department of the S. Matteo
Hospital, Pavia, Italy, between January 1992 and December
1998 for heart failure management and/or heart transplan-
tation evaluation who met the inclusion criteria: 1) moder-
ate to severe chronic heart failure; 2) significant LV systolic
dysfunction (left ventricular ejection fraction [LVEF]
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,35%); and 3) etiology of either primary dilated cardiomy-
opathy or ischemic heart disease. Idiopathic dilated cardio-
myopathy was defined as LV dysfunction in the absence of
significant coronary artery disease on coronary angiography
and in the absence of specific heart muscle disease or active
myocarditis on the endomyocardial biopsy. Ischemic heart
disease was diagnosed on the basis of documented previous
myocardial infarction or significant coronary artery disease
on coronary arteriography. We excluded from this series
patients with end-stage valvular heart disease, cardiac amy-
loidosis, hypertrophic cardiomyopathy, active alcoholism,
chronic obstructive pulmonary disease, recent acute myo-
cardial infarction (,6 months) or unstable angina. Patients
receiving infusion therapy with dopamine, dobutamine or
phosphodiesterase inhibitors at presentation were also
excluded.
All patients underwent right heart catheterization as part
of the diagnostic protocol for heart transplantation eligibil-
ity. Medical therapy was individually adjusted according to
a standardized treatment regimen, as previously reported
(4). The clinical characteristics of the patients are shown in
Table 1.
Right heart catheterization. After the patient had given
informed consent, a modified Swan-Ganz thermodilution
catheter mounted with a rapid-response thermistor (93A-
431H-7F, American Edwards Laboratories, Irvine, Califor-
nia) was inserted transcutaneously through the right internal
jugular vein and advanced until its tip was into the pulmo-
nary artery. The thermistor was connected to a dedicated
computer (REF-1 Ejection Fraction/Cardiac Output Com-
puter, American Edwards Laboratories) to display on-line
the cardiac output and RVEF (15,16). The protocol has
been previously described in detail (4). The following
hemodynamic variables were measured or derived: systemic
blood pressure (arm-cuff sphygmomanometer), right atrial
pressure, PAP, pulmonary wedge pressure, thermodilution
RVEF, cardiac output, cardiac index, systemic vascular
resistance and pulmonary vascular resistance. Thermodilu-
tion measurements were obtained in triplicate.
A mean PAP value .20 mm Hg was taken as the cut-off
for pulmonary hypertension. A RVEF value ,35% was
taken as the cut-off for RV systolic dysfunction; this value
was chosen as the median value of RVEF in our patients
with normal PAP. Based on the values of PAP and RVEF,
the study group was classified into four subgroups: normal
PAP/preserved RVEF, high PAP/low RVEF, high PAP/
preserved RVEF and normal PAP/low RVEF. Two pa-
tients were lost to follow-up and were therefore excluded.
Echocardiography. Standard M-mode, two-dimensional
and Doppler echocardiographic studies were performed
using either Toshiba SSA 270A (Toshiba Corporation,
Tokyo, Japan) or Esaote SIM 7000 Challenge (Esaote,
Florence, Italy) ultrasound equipment. Left ventricular di-
mensions were measured according to the recommendations
of the American Society of Echocardiography; end-diastolic
and end-systolic LV volumes were calculated according to
the single-plane, area–length method.
Statistical analysis. Data are shown as the mean value 6
SD for continuous variables and absolute or relative fre-
quencies for categorical variables. Correlations between
mean PAP and other hemodynamic variables were assessed
using linear regression analysis. Survival analysis was per-
formed according to the Cox regression method. The end
points of survival analysis were cardiac death or urgent heart
transplantation (status 1 according to the UNOS criteria)
(1). Elective heart transplantation was considered as a
censored observation with the patients withdrawn from the
analysis at the time of transplantation. Cumulative survival
was compared in the four subgroups of patients obtained
according to the presence or absence of pulmonary hyper-
tension and RV dysfunction. A p value ,0.05 was consid-
ered statistically significant. The statistical package Stata 6.0
Abbreviations and Acronyms
LV 5 left ventricle or ventricular
LVEF 5 left ventricular ejection fraction
NYHA 5 New York Heart Association
PAP 5 pulmonary artery pressure
RV 5 right ventricle or ventricular
RVEF 5 right ventricular ejection fraction
Table 1. Clinical Characteristics of the Study Group (n 5 379)
Age (yrs) 51 6 10
Gender (M/F) 323/56
NYHA functional class
II 30%
III 54%
IV 16%
Etiology
DCM 66%
IHD 34%
PCWP (mm Hg) 19.4 6 10.9
PAP (mm Hg) 27.9 6 13.7
CI (liters/min per m2) 2.2 6 0.7
RVEF (%) 24.1 6 13
RAP (mm Hg) 5.2 6 5.7
LVEF (%) 21.8 6 6.7%
Therapy
Diuretics 100%
ACE inhibitors 92%
Digitalis 73%
Oral anticoagulant 56%
Nitrates 54%
Spironolactone 43%
Amiodarone 36%
Beta-blockers 35%
Antiplatelets 18%
Data are presented as the mean value 6 SD or percentage of patients, except for
gender, presented as number of patients.
ACE 5 angiotensin-converting enzyme; CI 5 cardiac index; DCM 5 dilated
cardiomyopathy; F 5 female; IHD 5 ischemic heart disease; LVEF 5 left ventricular
ejection fraction; M 5 male; NYHA 5 New York Heart Association; PAP 5
pulmonary artery pressure; PCWP 5 pulmonary capillary wedge pressure; RAP 5
right atrial pressure; RVEF 5 right ventricular ejection fraction.
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(Stata Corporation, College Station, Texas) was used for
computations.
RESULTS
Spectrum of PAP in the entire study group. A mean PAP
value .20 mm Hg was found in 236 of 379 patients. As
compared with the 143 patients with normal PAP, the
patients with pulmonary hypertension were more frequently
in New York Heart Association (NYHA) functional class
III or IV (83% vs. 46%, p , 0.000), had a lower cardiac
index (2 6 0.6 vs. 2.6 6 0.6 liters/min per m2, p , 0.000),
a lower RVEF (19 6 11% vs. 34 6 8%, p , 0.000) and a
higher right atrial pressure (7.6 6 5 vs. 1.2 6 3 mm Hg,
p , 0.000). Mean PAP and pulmonary capillary wedge
pressure were found to be strongly related (r 5 0.85, p ,
0.000) (Fig. 1).
Relation between PAP and RV function. A significant
inverse relation, in a context of a wide scattering of the data,
was found between mean PAP and RVEF (r 5 20.66; p 5
0.000). This relation was similar between patients with
dilated cardiomyopathy and those with ischemic heart
disease (Fig. 2).
Prognostic independence of PAP and RV function. On
univariate analysis, several variables were found to be sig-
nificantly (p , 0.05) related to survival (NYHA class III or
IV, LV end-systolic diameter index, LVEF, mean PAP,
pulmonary capillary wedge pressure, right atrial pressure,
cardiac index, pulmonary vascular resistance, systemic vas-
Figure 1. Relation between mean pulmonary artery pressure (PAP) and pulmonary capillary wedge pressure (PCWP).
Figure 2. Relation between mean pulmonary artery pressure (PAP) and right ventricular ejection fraction (RVEF) in patients with dilated cardiomyopathy
(DCM 5 continuous line, open squares) and in patients with ischemic heart disease (IHD 5 dotted line, open triangles).
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cular resistance and RVEF). All these variables were in-
cluded in the multivariate model, with the exception of
pulmonary vascular resistance, which was co-linear with
systemic vascular resistance, and pulmonary capillary wedge
pressure, which was co-linear with mean PAP. No interac-
tion was found between mean PAP and RVEF. Cox
multivariate analysis identified four independent prognostic
predictors of mortality or urgent transplantation: NYHA
class III or IV, RVEF, mean PAP and LV end-systolic
diameter index (Table 2).
Prognostic stratification according to the coupling be-
tween PAP and RV function. Table 3 summarizes the
clinical, echocardiographic and hemodynamic characteris-
tics of the four subgroups of patients, obtained according to
the presence or absence of pulmonary hypertension and RV
dysfunction. During a median follow-up period of 17.2
months, 105 patients (28%) died and 35 patients (9.2%)
underwent urgent heart transplantation. Of the 105 ob-
served deaths, 39 were attributed to sudden death and 66 to
progressive heart failure. The median time to death was 11.2
months, and the median time to urgent heart transplanta-
tion was 7.6 months. The median survival of the entire
study group was 33.9 months.
During the follow-up period, 86 patients died and 29
underwent urgent transplantation in the high PAP/low
RVEF group (n 5 215); five patients died and one under-
went urgent transplantation in the high PAP/preserved
RVEF group (n 5 21); nine patients died in the normal
PAP/preserved RVEF group (n 5 73); and five patients
died and five underwent urgent transplantation in the
normal PAP/low RVEF group (n 5 68). On Cox survival
analysis, the patients in the high PAP/low RVEF group had
the worst prognosis: their hazards ratio was seven times higher
than that of the patients in the normal PAP/preserved RVEF
group (95% confidence interval [CI] 3.6 to 14.1, p 5 0.000),
4.3 times higher than that of the patients in the high PAP/
preserved RVEF group (95% CI 2.2 to 8.2, p 5 0.000) and 3.3
times higher than that of the patients in the normal PAP/low
RVEF group (n 5 68) (95% CI 1.5 to 7.2, p , 0.002). The
prognoses of the patients in the normal PAP/preserved RVEF
group, in the normal PAP/low RVEF group and in the high
PAP/preserved RVEF group were not statistically different
(Fig. 3).
Table 2. Results From Cox Multivariate Analysis of Survival
Variable
Hazards
Ratio
95%
Confidence
Interval
p
Value
RVEF (per each 5-U decrement) 1.26 1.10–1.46 0.001
NYHA functional class
(III or IV vs. II)
2.7 1.4–5.1 0.003
LVESDI (per each 5-mm
increment)
1.20 1.04–1.40 0.013
Mean PAP (per each 5-mm Hg
increment)
1.10 1.0–1.21 0.047
Model p value 5 0.000; likelihood ratio by chi-square (8) 5 122.04.
LVESDI 5 left ventricular end-systolic diameter index; other abbreviations as in
Table 1.
Table 3. Characteristics of the Patients Grouped According to the Coupling Between
Pulmonary Artery Pressure and Right Ventricular Ejection Fraction
Normal
PAP/Preserved
RVEF
(Group 1, n 5 73)
Normal
PAP/Low
RVEF
(Group 2, n 5 68)
High
PAP/Preserved
RVEF
(Group 3, n 5 21)
High
PAP/Low
RVEF
(Group 4, n 5 215)
Gender (M/F) 62/11 53/15 20/1 186/29
Age (years) 52 6 10 51 6 11 52 6 10 51 6 10
Etiology (DCM/IHD) 53/20 51/17 14/7 132/83
NYHA functional class
III or IV (%)
40% 53% 48% 87%*
HR (beats/min) 75 6 13 79 6 14 75 6 17 88 6 18*
Rhythm (SR/AF) 69/4 49/19† 21/0 165/50†
LBBB/RBBB (%) 53/3 39/6 48/5 43/7
Bilirubin, direct (mg) 0.17 6 0.11 0.20 6 0.16 0.23 6 0.18 0.77 6 0.31*
LVEF (%) 25.1 6 5.8 22.9 6 6.2 23.8 6 6.2 20.6 6 5.7‡
LVEDDI (mm) 39 6 7 40 6 5 39 6 5 41 6 6
LVESDI (mm) 33 6 6 34 6 5 33 6 5 35 6 6
PAP (mm Hg) 13 6 4 13.8 6 3.8 29 6 8.6§ 37.4 6 9.1§
PCWP (mm Hg) 8.2 6 4.3 8.1 6 3.6 20.3 6 8.8§ 26.6 6 7.4§
RAP (mm Hg) 1.2 6 3.7 1.3 6 2.3 4.5 6 4.3§ 7.9 6 5.7*
CI (ml/min per m2) 2.7 6 0.6 2.5 6 0.6 2.6 6 0.6 1.9 6 0.6*
RVEF (%) 42 6 5 27 6 7† 41 6 5 16 6 8†
Therapy
Nitrates (%) 45\ 38\ 71 62
Frusemide (mg) 45 6 46 64 6 60 67 6 41 105 6 122*
*p , 0.05 vs. all other groups. †p , 0.05 vs. groups 1 and 3. ‡p , 0.05 vs. group 1. §p , 0.05 vs. groups 1 and 2. \p , 0.05
vs. groups 3 and 4.
AF 5 atrial fibrillation; HR 5 heart rate; LBBB 5 left bundle branch block; LVEDDI 5 left ventricular end-diastolic
diameter index; RBBB 5 right bundle branch block; SR 5 sinus rhythm; other abbreviations as in Tables 1 and 2.
186 Ghio et al. JACC Vol. 37, No. 1, 2001
How RV Function Relates to PAP in Heart Failure January 2001:183–8
DISCUSSION
The results of this study are likely to have a significant
impact on the management of patients assessed for heart
transplantation. As a general rule, increased PAP is coupled
with reduced systolic function of the RV and is clinically
associated with a poor prognosis. However, exceptions to
this rule may occur frequently in clinical practice, so that a
refinement of the prognostic stratification of the patients
with chronic heart failure requires the knowledge of both
PAP and RV function.
Coupling between RV function and PAP. The finding of
an inverse relation between RV systolic function and PAP is
in accordance with most previous pathophysiologic studies
(7–12,17). Interestingly, this relation was similar between
patients with dilated cardiomyopathy and those with isch-
emic heart disease, supporting the concept that in patients
with heart failure due to primary dilated cardiomyopathy or
to ischemic heart disease, the major determinant of the
impairment in systolic function of the RV is afterload
mismatch. Our data demonstrate that exceptions to the
physiologic relation between mean PAP and RVEF may be
observed frequently in clinical practice. First, RV function
may be preserved despite elevated PAP. A possible expla-
nation for this finding is that the development of RV
dysfunction in response to an increase in afterload is
time-dependent. This is impossible to prove without defin-
ing, in each patient, the duration of pulmonary hyperten-
sion; however, liver function tests were found to be
abnormal only in patients with pulmonary hypertension and
RV dysfunction, reflecting either the greater hemodynamic
derangement or, possibly, a longer duration of the RV
overload (18,19). An alternative hypothesis is that more
favorable RV remodeling could determine better function in
some patients. This seems unlikely because the ultrasound
exploration did not show evidence of RV hypertrophy in any
of these patients; furthermore, to our knowledge, no patho-
logic or clinical study has ever described RV hypertrophy in
patients with heart failure due to ischemic heart disease or
primary dilated cardiomyopathy. Second, RV dysfunction
may be observed even in patients with normal PAP.
Unexpectedly, this group of patients was fairly large (68 of
379 patients). There are several possible explanations for
this finding: in patients with advanced disease, a low cardiac
output state could determine normal PAP associated with
reduced RV function; however, given the good prognosis of
this group as a whole, it is unlikely that more than a few
patients were in such a condition. A primary reduction in
contractility could be responsible for the compromised RV
function (17). The data, however, do not support such a
hypothesis. In fact, there was a slightly greater prevalence of
patients with dilated cardiomyopathy in the normal PAP/
low RVEF group (p 5 NS). Overtreatment with diuretic
drugs is another likely explanation, although in this group,
the daily dose of frusemide was significantly lower than that
of the patients in the high PAP/low RVEF group and
similar to that of the other groups. Finally, a high prevalence
of atrial fibrillation was observed in patients with normal
PAP and low RVEF, leading to the hypothesis that the
absence of active atrial contraction could play a major role in
the pathogenesis of RV dysfunction.
Prognosis of patients with heart failure according to RV
function and PAP. The demonstration that exceptions can
be found to the general rule that inversely relates PAP and
RV function is not only a matter of physiologic speculation
but also of great clinical value in the prognostic stratification
of patients with advanced heart failure. The clinical impli-
cations of these findings are twofold. First, in patients with
heart failure and normal PAP, the assessment of RV function
Figure 3. Survival rates without urgent heart transplantation in patients grouped according to the coupling between mean pulmonary artery pressure (PAP)
and right ventricular ejection fraction (RVEF). Group 1 5 normal PAP/preserved RVEF (n 5 73); group 2 5 normal PAP/low RVEF (n 5 68); group
3 5 high PAP/preserved RVEF (n 5 21); and group 4 5 high PAP/low RVEF (n 5 215).
187JACC Vol. 37, No. 1, 2001 Ghio et al.
January 2001:183–8 How RV Function Relates to PAP in Heart Failure
does not seem to improve the prognostic stratification. In
contrast, when PAP is high at rest despite optimized medical
therapy, the prognosis of the patients is strongly related to RV
performance. For example, reduced RVEF is a harbinger of
high risk of death or urgent transplantation, whereas preserved
RVEF implies a prognosis that is very similar to that of
patients with normal PAP.
Study limitations. The complex geometry of the RV
makes it difficult to assess the systolic function of this
cardiac chamber. No technique is exempt from potential
criticism. Thermodilution-derived RVEF may be inaccurate
in patients with high and irregular heart rates and in
patients with severe tricuspid regurgitation; given these
limitations, this technique has been well validated and has
proved to be useful in several clinical conditions (4,15,16).
Cardiopulmonary exercise testing would have helped to
better stratify the risk of these patients and to verify whether
the association between reduced RVEF and normal PAP,
though not negatively affecting the prognosis, could be
responsible for a lower exercise tolerance. Finally, in hu-
mans, there is considerable variability in the extent of
increased PAP in response to pulmonary venous hyperten-
sion. Because this was not an objective of the present study,
the results do not help to clarify why pulmonary hyperten-
sion develops in patients with heart failure due to ischemic
heart disease or primary dilated cardiomyopathy. These
issues might be the subject of future investigations.
Conclusions. These observations emphasize the necessity of
combining the right heart hemodynamic variables with a
functional evaluation of the RV when trying to define the
individual risk of patients with chronic heart failure. Although
we obtained all of the data during right heart catheterization
(using a rapid-response thermodilution catheter to measure
RVEF), such an integrated evaluation should also be easily
performed with other techniques—in particularly, by means of
the ultrasound evaluation, which allows a noninvasive estimate
of both PAP and RV function.
Reprint requests and correspondence: Dr. Stefano Ghio, Dipar-
timento di Cardiologia, Policlinico S. Matteo, Piazza Golgi 1,
27100 Pavia, Italy. E-mail: s.ghio@smatteo.pv.it.
REFERENCES
1. Mudge GH, Goldstein S, Addonizio LJ, et al. Task Force 3: recipient
guidelines/prioritization. Presented at the 24th Bethesda Conference:
Cardiac Transplantation. J Am Coll Cardiol 1993;22:21–31.
2. Polak JF, Holman L, Wynne J, Colucci WS. Right ventricular ejection
fraction: an indicator of increased mortality in patients with congestive
heart failure associated with coronary artery disease. J Am Coll Cardiol
1983;2:217–24.
3. Di Salvo TG, Mathier M, Semigran MJ, Dec WG. Preserved right
ventricular ejection fraction predicts exercise capacity and survival in
advanced heart failure. J Am Coll Cardiol 1995;25:1143–53.
4. Gavazzi A, Berzuini C, Campana C, et al. Value of right ventricular
ejection fraction in predicting short-term prognosis of patients with
severe chronic heart failure. J Heart Lung Transplant 1997;16:774–
85.
5. De Groote P, Millaire A, Foucher-Hossein C, et al. Right ventricular
ejection fraction is an independent predictor of survival in patients
with moderate heart failure. J Am Coll Cardiol 1998;32:948–54.
6. Karasatakis GT, Karagounis LA, Kalyvas PA, et al. Prognostic
significance of echocardiographically estimated right ventricular short-
ening in advanced heart failure. Am J Cardiol 1998;82:329–34.
7. Brent BN, Berger HJ, Matthay RA, Mahler D, Pytlik L, Zaret BL.
Physiologic correlates of right ventricular ejection fraction in chronic
obstructive pulmonary disease: a combined radionuclide and hemody-
namic study. Am J Cardiol 1982;50:255–62.
8. Sibbald WJ, Driedger AA, Myers ML, Short AI, Well GA. Biven-
tricular function in the adult respiratory distress syndrome: hemody-
namic and radionuclide assessment with special emphasis on right
ventricular function. Chest 1983;84:126–34.
9. Morrison D, Goldman S, Wright AL, Henry L, Sorenson S, Caldwell
J, Ritchie J. The effect of pulmonary hypertension on systolic function
of the right ventricle. Chest 1983;84:250–7.
10. Brown KA, Okada RD, Boucher CA, Strauss HW, Pohost GM.
Right ventricular ejection fraction response to exercise in patients with
coronary artery disease influence of both right coronary artery disease
and exercise-induced changes in right ventricular afterload. J Am Coll
Cardiol 1984;3:895–901.
11. Konstam MA, Salem DN, Isner JM, at al. Vasodilator effect on right
ventricular function in congestive heart failure and pulmonary hyper-
tension: end-systolic pressure-volume relation. Am J Cardiol 1984;54:
132–6.
12. Oldershaw P. Assessment of right ventricular function and its role in
clinical practice. Br Heart J 1992;68:12–5.
13. Abramson SV, Burke JF, Kelly JJ Jr., et al. Pulmonary hypertension
predicts mortality and morbidity in patients with dilated cardiomyop-
athy. Ann Intern Med 1992;116:888–95.
14. Hunt SA. Pulmonary hypertension in severe congestive heart failure:
how important is it? J Heart Lung Transplant 1997;16:S13–5.
15. Spinale FG, Smith AC, Carabello BA, Crawford FA. Right ventric-
ular function computed by thermodiluition and ventriculography.
J Thorac Cardiovasc Surg 1990;99:141–52.
16. Hurford WE, Zapol WM. The right ventricular illness: a review of
anatomy, physiology and clinical evaluation of its function. Intensive
Care Med 1988;14:448–57.
17. Juilliere Y, Buffet P, Marie PY. Comparison of right ventricular
systolic function in idiopathic dilated cardiomyopathy and healed
anterior wall myocardial infarction associated with atherosclerotic
coronary artery disease. Am J Cardiol 1994;73:588–90.
18. Batin P, Wickens M, McEntegart D, Fullwood L, Cowley AJ. The
importance of abnormalities of liver function tests in predicting
mortality in chronic heart failure. Eur Heart J 1995;16:1613–8.
19. Kubo SH, Walter BA, John DHA, Clark M, Cody RJ. Liver function
abnormalities in chronic heart failure. Arch Intern Med 1987;147:
1227–30.
188 Ghio et al. JACC Vol. 37, No. 1, 2001
How RV Function Relates to PAP in Heart Failure January 2001:183–8
